We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Navidea Biopharmaceuticals Inc | AMEX:NAVB | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0779 | 0 | 01:00:00 |
Date of Report (date of earliest event reported):
|
December 14, 2021
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35076
|
31-1080091
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
4995 Bradenton Avenue, Suite 240, Dublin, Ohio
|
43017
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(614) 793-7500
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
Common Stock, par value $.001 per share
|
NAVB
|
NYSE American
|
Item 1.02 | Termination of a Material Definitive Agreement. |
Item 8.01 | Other Events. |
Item 9.01. | Financial Statements and Exhibits. |
(a) Not applicable. | |
(b) Not applicable. | |
(c) Not applicable. | |
(d) Exhibits |
Exhibit No. | Description |
99.1 | Press Release dated December 15, 2021 |
99.2 | Press Release dated December 15, 2021 |
99.3 | Press Release dated December 16, 2021 |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Navidea Biopharmaceuticals, Inc.
|
||
Date: December 16, 2021
|
By:
|
/s/ Michael S. Rosol
|
Michael S. Rosol, Ph.D.
Senior Vice President and Chief Medical Officer
|
1 Year Navidea Biopharmaceuticals Chart |
1 Month Navidea Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions